The FDA held just 14 drug advisory committee meetings in 2025, a 72% decline from 38 the prior year, according to a STAT News analysis. The collapse in public advisory panels comes as the agency faces a string of contentious drug approval decisions. In one striking episode, the FDA bypassed its standard advisory process entirely and instead held a private press conference where officials anonymously criticized a Huntington’s disease treatment — a procedural maneuver with no recent precedent. The retreat from public deliberation marks a fundamental shift in how the nation’s drug regulator engages with outside scientific expertise.

FDA advisory committees have served for decades as the primary mechanism for injecting independent scientific review into the drug approval process. These panels — composed of outside physicians, researchers, statisticians, and patient advocates — deliberate in public, with transcripts and votes on the record. Their recommendations are non-binding but carry enormous weight with prescribers, payers, and investors. The 72% reduction is not simply a scheduling anomaly; it reflects a broader pattern of institutional contraction at HHS under the current administration, where staffing cuts, leadership vacancies, and political pressure have eroded the agency’s capacity and willingness to convene external review.

For health systems, providers, and pharmacy benefit managers, the erosion of FDA advisory transparency creates real operational risk. Advisory committee proceedings generate the clinical evidence summaries and vote margins that inform formulary decisions, prior authorization criteria, and treatment guidelines. Without public deliberation, payers lose a critical input for coverage determinations, and providers lose visibility into the risk-benefit debates that shaped approval. Drug manufacturers face a different calculus: fewer public panels may accelerate some approvals but undermine post-market credibility. For dental and medical practices alike, the downstream effect is a less predictable regulatory environment — new therapies may reach market with thinner public vetting, complicating clinical adoption and liability assessments.

Watch for whether Congress intervenes to mandate minimum advisory committee convening thresholds — bipartisan concern over FDA independence has been building since late 2025. Track how major payers respond: if CVS Caremark, Express Scripts, or UnitedHealthcare begin citing the absence of advisory committee review as grounds for restricting coverage of newly approved drugs, the commercial impact will be immediate. Monitor FDA staffing numbers through the end of Q2 2026 — the agency’s Center for Drug Evaluation and Research has seen significant attrition, and further departures could make even 14 meetings unsustainable in the current fiscal year.